Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab vs placebo in advanced hepatocellular carcinoma after sorafenib
CTR20170561Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ramucirumab in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Started Jun 2017; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20170561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170561.